Group Intervention on Executive Function in Children With Autism Spectrum Disorder

Last updated: July 27, 2023
Sponsor: Istituto per la Ricerca e l'Innovazione Biomedica
Overall Status: Active - Recruiting

Phase

N/A

Condition

Asperger's Disorder

Williams Syndrome

Autism

Treatment

ApisMela protocol

"Unstuck and on Target" protocol

Clinical Study ID

NCT05977075
CNR-IRIB-PRO-2023-003
  • Ages 7-13
  • All Genders

Study Summary

Autism is a developmental disorder characterized by difficulties in social communication, repetitive behaviors, and social interaction. A key aspect of autism concerns executive functions, which are a set of cognitive processes that regulate attention, planning, inhibition, and impulse control. These functions are often impaired in children with autism, affecting their learning and daily functioning.

The present protocol aims to test the first absolute and then comparative effectiveness of two executive function development programs: the "APISMELA" training and the "UNSTUCK & ON TARGET! SECOND EDITION". Two groups will be held at the same time and will conduct the two programs in reverse order. In fact, the protocol is divided into two phases.

Participants subjected to the APISMELA group, finished the intervention sessions will conduct an interim evaluation and then begin the intervention phases of the UNSTUCK & ON TARGET! SECOND EDITION protocol.

Participants subjected to the UNSTUCK & ON TARGET! SECOND EDITION group, finished the intervention sessions will conduct an interim evaluation and then begin the intervention phases of the APISMELA protocol.

Group intervention programs were chosen for two reasons: group intervention compared with individual intervention have lower costs for patients and their families and thus higher overall social acceptability. The second is that group intervention within the social-constructivist paradigm, to which the two chosen programs belong, becomes a fundamental resource for stimulating that augmentative learning that is a source of development on the cognitive and conceptual levels for human beings.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Children with diagnosis of autism and autism spectrum disorder

Exclusion

Exclusion Criteria:

  • Presence of other medical disorders

Study Design

Total Participants: 12
Treatment Group(s): 2
Primary Treatment: ApisMela protocol
Phase:
Study Start date:
December 01, 2022
Estimated Completion Date:
March 31, 2024

Connect with a study center

  • Institute for Biomedical Research and Innovation (IRIB) - National Research Council (CNR)

    Messina, 98164
    Italy

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.